Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by lonc17on Feb 07, 2024 6:58pm
298 Views
Post# 35868740

Advertising

AdvertisingONC has very limtied funds left (less than 10 months) and almost no avenue to raise any capital, yet they continue to spend money on paid promotional "News" articles. 

This type of promotional conduct is generally limited to OTC microcap companies but it appears to be MC"s primary skill set and the only thing he is able to contribute to ONC at this moment in time.

No doubt we'll see dozens more of these "articles" flood the internet in the next few weeks prior to ONC doing a reverse split and issuing more shares in a desperate attempt to stay afloat. 

https://www.marketwatch.com/press-release/pancreatic-cancer-treatments-poised-for-major-advances-in-2024-e3eb84eb




<< Previous
Bullboard Posts
Next >>